Metastatic Hepatic Epithelioid Hemangio-Endothelioma: Long-Term Response to Sunitinib Malate

作者：Saada Esma^*; Saint Paul Marie Christine; Gugenheim Jean; Follana Philippe; Francois Eric

来源：Oncology Research and Treatment, 2014, 37(3): 124-126.

DOI：10.1159/000360208

• Epithelioid hemangio-endotheliomau
• Antiangiogenic therapy
• Sunitinib

Background: Epithelioid hemangio-endothelioma (EHE) is a rare malignant tumor of vascular origin that electively metastasizes to lungs and liver. Case report: We report the case of a 51-year-old woman with metastatic and progressive EHE of the liver. She was successfully treated with daily administration of sunitinib malate, an oral multi-target tyrosine kinase inhibitor, which particularly targets vascular endothelial growth factor (VEGF) receptors. Stabilization has lasted 6 years. We discuss the rationale for using antiangiogenic treatment for EHE. Conclusion: This case adds to a growing body of evidence that suggests that antiangiogenic agents should be considered in patients who present with advanced EHE.

• 出版日期2014-3